Physician profile
Marion K Studebaker
NPI 1306875729
$12,981.29
in general payments reported to CMS, 2019-2025
46 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $1,664 · 2021: $2,961 · 2022: $1,996 · 2023: $1,828 · 2024: $1,730 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,962 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,414.39 | 2019-2025 | |
| Lilly USA, LLC | $1,286.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,268.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,114.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,053.01 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $919.31 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $847.19 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $812.83 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $498.23 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $470.12 | 2019-2022 | |
| Amgen INC. | $450.66 | 2019-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $396.85 | 2019-2023 | Steglatro, Belsomra, Segluromet |
| Abbott Laboratories | $371.64 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $266.10 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.27 | 2021-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Studebaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.